Factor VIIa
FAST
In adult patients with acute intracerebral hemorrhage treated within 4 hours of onset, does recombinant activated factor VII (rFVIIa) at doses of 20 μg/kg or 80 μg/kg, compared with placebo, reduce death or severe disability at 90 days?
More topics:
- Acute Blood Pressure Control
- Andexanet Alfa
- Anti-fibrinolytic Therapy
- Anticoagulant Reversal
- Antiplatelet Therapy Complications
- Craniotomy
- Deferoxamine
- External Ventricular Drain (EVD)
- Factor VIIa
- Factor Xa Inhibitor Reversal
- Fever Prevention
- Fresh Frozen Plasma (FFP)
- Glucose Control
- Hematoma Evacuation
- Hematoma Expansion
- Hemostasis
- Imaging Biomarkers
- Insulin Therapy
- Intraventricular Hemorrhage
- Iron Chelation
- Ischemic Stroke Management
- Minimally Invasive Surgery
- Neurocritical Care
- Neuroprotection
- Neurosurgical Intervention
- Prothrombin Complex Concentrate (PCC)
- Reversal Agents
- Secondary Brain Injury
- Supportive Care
- Temperature Management
- Thrombolysis (Alteplase)
- Tranexamic Acid
- Warfarin Reversal